ArticleBiomaterials and biosystems2025
Engineered dermal tissue constructs using mesenchymal stromal cells and TGF-β3-loaded electrospun dressings for stimulated wound healing process.
Article in Biomaterials and biosystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor-beta 3 (TGF-β3) has been shown to promote wound healing by regulating key cellular processes. However, its clinical application is limited by the need for repeated dosing and by its labile nature, as TGF-β3 is sensitive to physiological fluctuations in temperature and pH, which can compromise its stability and efficacy. In this study, we developed a novel scaffold composed of poly(ε-caprolactone) and type I collagen as a matrix to immobilize calcium alginate capsules loaded with TGF-β3, called PCAT. This system enables localized delivery of the factor to the lesion site while preserving its bioactivity, positioning PCAT as an effective growth factor-release platform. In vitro characterization using human Wharton's jelly mesenchymal stromal cells (hWJ-MSCs) cultured on PCAT was conducted to assess cytocompatibility, bioactivity and growth factor quantification. Additionally, the tissue construct formed by hWJ-MSCs and PCAT was evaluated in vivo using full-thickness wound and epidermal skin grafts. The results demonstrated that PCAT preserved TGF-β3 - bioactivity, enabled sustained and localized delivery, promoted hWJ-MSCs proliferation, and modulated the secretion of growth factors associated with skin wound healing in vitro. Histological analysis showed that PCAT/hWJ-MSCs promoted epidermal skin grafts integration, evidenced by the presence of epidermal ridges (ER) and dermal papillae (DP). In addition, granulation tissue was characterized by thick and long collagen fibers, well-formed blood vessels (BV), and a low prevalence of inflammatory cells (IC). These results suggest that PCAT/hWJ-MSCs construct effectively stimulates wound healing and represents a promising strategy for skin tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.